Tenax Therapeutics, Inc. (TENX)
Fuera de horario:
Tenax Therapeutics, Inc.
101 Glen Lennox Drive
Suite 300
Chapel Hill, NC 27517
United States
919 855 2100
https://www.tenaxthera.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 5
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Christopher T. Giordano | CEO, President & Director | 644.77k | N/D | 1975 |
| Dr. Stuart Rich M.D. | Chief Medical Officer & Director | 481.22k | N/D | 1950 |
| Mr. Lawrence R. Hoffman CPA, Esq. | Interim Chief Financial Officer | N/D | N/D | 1955 |
| Mr. Doug Randall | Executive Vice President of Commercial & Business Operations | N/D | N/D | N/D |
| Dr. Douglas Hay | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Descripción
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Gestión corporativa
La calificación ISS Governance QuickScore de Tenax Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
